DIRS.INFO The most relevant business & tech news

☆ New York Democrats are desperate to avoid repeat of their 2022 midterm collapse
▼ + stars: | 2024-09-18 | by ( Gregory Krieg | Gloria Pazmino | ) edition.cnn.com time to read: +12 min

New York Democrats offered a wide array of excuses for their disastrous 2022 midterms, when Republicans flipped four seats outside New York City on their way to winning a narrow US House majority. Now, less than two months out from the 2024 general election, the state party, its campaign season allies, chastened candidates and Gov. D’Esposito is one of five New York GOP freshmen facing an onslaught from Democrats determined to claw back suburban voters. “New York is the reason Democrats lost the House in 2022,” said Pamela Shifman, president of the Democracy Alliance, a liberal group spending big in New York this year. “There’s more focus than there was the last couple cycles, both from the state party, but also obviously the national committees,” the strategist said.

Persons: Kathy Hochul, Donald Trump’s, Anthony D’Esposito’s, Laura Gillen, Joe Biden, Gillen, Marc Molinaro, Mike Lawler, Nick LaLota, Brandon Williams, Kamala Harris, ”, Pamela Shifman, Nancy Pelosi, Pelosi, “, Jay Jacobs, ” Hochul, Andrew Caballero, Reynolds, Ana María Archila, Archila, Trump, Hakeem Jeffries, Jeffries, Kirsten Gillibrand, Lizzy Weiss, Hochul, Andrew Cuomo, Tom Suozzi, Republican George Santos, Gabby Seay, Chip Somodevilla, “ Jeffries, “ He’s, Seay, Michael Bloomberg, Elizabeth Frantz, Lawler, Sean Patrick Maloney, Mondaire Jones, ” Lawler, Jones, Roe, Lee Zeldin, Riley Gaines Organizations: CNN, New York Democrats, Republicans, Gov, Democratic, Republican Rep, New York GOP, Trump, Democracy Alliance, Politico, Democratic National Convention, New, Getty, Families Party, Democratic Congressional, Committee, New York’s, Republican, ”, Capitol Visitor Center, GOP, PAC, New York Fund, Empire, New York, Congressional, Democrats, Rep, “, Working, Party, US, Wade, Convention Locations: New York City, Long, York, Hudson, Central New York, “ New York, New York, Chicago, AFP, Washington ,, strategizing, strategize, Gaza, Suozzi, Hudson Valley, State

NEW YORK (AP) — A prosecutor in Manhattan announced six additional indictments of men allegedly involved in a brawl with police officers in Times Square, but he said investigators were still working to identify several suspects and their exact role in the frenzy. “We have to ensure we identify and charge those individuals who actually committed criminal acts in this matter,” Bragg said. The man allegedly at the center of the conflict, Yohenry Brito, 24, was indicted on charges including two counts of assault by a grand jury on Tuesday and is being held on Rikers Island. He has said that only a “small minority” of new arrivals were participating in illegal behavior, but he has faced allegations of weaponizing the Times Square incident for political gain. Earlier this week, members of the Guardian Angels were seen roughing up a man in Times Square during a live television interview on Fox News.

Persons: —, Alvin Bragg, Bragg, ” Bragg, “, Wilson, Kelvin Servita Arocha, Yohenry Brito, Joseph Kenny, Brito “, Kenny, Eric Adams, ”, Ana María Archila, Curtis Sliwa Organizations: Times, District, Police, NYPD, . New, . New York City, New York, Families Party, ” Police, Guardian Angels, Fox News Locations: Manhattan, Wilson Juarez, Rikers, ., . New York, ”

"We're going to start seeing two big waves of growth" in Mexican startups, said Eric Perez-Grovas, co-founder of venture capital fund Wollef, in an interview, adding an earlier slowdown in financing activity was starting to reverse. Mexico's startups are looking to recover after a lackluster year, hit by rising inflation and high interest rates, dampened investment prospects. "The economic outlook is really, really positive, inflation is coming down and employment is steady. Nexu, an auto-financing startup, landed a $20-million investment round last month, adding onto $53 million it had previously raised. Nexu's round was oversubscribed and had buy-in from foreign investors, however, showing market appetite is increasing, said Perez-Grovas.

Persons: Edgard Garrido, Eric Perez, Melonn, Andres Felipe Archila, Perez, Grovas, Abdon Necif, Kylie Madry, Sarah Morland, Rod Nickel Organizations: REUTERS, MEXICO CITY, Mexico's, Wollef, Thomson Locations: MEXICO, Mexico, U.S

☆ Wells Fargo’s top fourth-quarter trade ideas include a biopharma stock that could rally 60% off a new treatment
▼ + stars: | 2023-10-06 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

As investors approach year-end, Wells Fargo is offering its top high-conviction and catalyst-driven trade ideas for the fourth quarter of 2023. Question marks notwithstanding, analysts at Wells Fargo recently shared their top 10 tactical ideas for the next three months. But the worst could now be over, wrote analyst Derek Archila. APLS YTD mountain APLS YTD chart Within technology, Wells Fargo highlighted Microsoft as a top pick. Wells Fargo also included hotel and casino company Caesars Entertainment and discount retailer Ollie's Bargain Outlet among its top trade ideas for the fourth quarter.

Persons: Derek Archila, Wells, Michael, Matt Akers, Akers, Wells Fargo, — CNBC's Michael Bloom Organizations: Nasdaq, Wells, Microsoft, Aerospace, L3Harris Technologies, Caesars Entertainment Locations: Wells Fargo, 3Q23

Viridian Therapeutics is "a sight for sore eyes," according to Wells Fargo. Viridian's thyroid eye disease treatment VRDN-001 is currently undergoing clinical testing. Wells Fargo is confident it will gain market share even with Horizon's Tepezza already established in the market. Results for VRDN-001's phase one and two trials in chronic thyroid eye disease are expected in the second half of 2023. VRDN 1Y mountain Viridian Therapeutics stock —CNBC's Michael Bloom contributed to this report.

☆ Wells Fargo says this biopharmaceutical stock could double due to drug catalysts
▼ + stars: | 2023-03-21 | by ( Alex Harring | ) www.cnbc.com time to read: +1 min

Catalysts coming for Ventyx 's immunology and inflammation projects could help the stock more than double its share value, Wells Fargo said. Analyst Derek Archila initiated coverage of the biopharmaceutical stock at overweight and set a target price for the stock at $77. His price target implies the stock will surge 103.4% over the next year from where it closed Monday. But Archila said there's a likely chance that the company could set a new bar with its trial for moderately to severely active ulcerative colitis. Wall Street expectations for the read-out coming in the second half of this year would be "highly impressive" if met, Archila said.

☆ This under-the-radar biotech stock can surge 40% on upcoming cancer treatment data, Wells Fargo says
▼ + stars: | 2023-03-09 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

It's time to buy Exelixis shares ahead of readouts on the biotech firm's cancer treatment, according to Wells Fargo. Analyst Derek Archila initiated coverage of Exelixis with an overweight rating, saying the biotech company's consistent revenue growth and upcoming clarity around the firm's cancer product called cabozantinib will drive upside. "We like cabo's near-term growth prospects and believe upcoming clarity on its [loss of exclusivity] will serve as a catalyst for shares. Exelixis shares are 2% higher this year, after falling 12% in 2022. EXEL 1D mountain Exelixis shares 1-day —CNBC's Michael Bloom contributed to this report.

Search resuls for: "Archila"

7 mentions found